European Autoimmune Disease Diagnostics Market Growth, Trends and Forecasts (2017 - 2022)

The Europe Autoimmune Disease Diagnostic Market for the period (2017 - 2022) is expected to account for USD XX billion at a CAGR of XX% from USD XX billion on 2015. Autoimmune diseases are a group of diseases characterized by inflammatory reactions caused by immune responses mistakenly generated against body tissues.

The term autoimmune disease refers to a varied group of illnesses that involve almost every human organ system. Environmental, infectious, and genetic factors play an important role in initiating or exacerbating autoimmune diseases.

The European Autoimmune Disease Market is driven by various factors like growing public awareness about the disease condition, improvement in laboratory automations, increasing partnerships between physicians and clinical laboratories and technological innovations. However, the market is restrained by the slow turnaround time for autoimmune disease diagnostic test result and the high frequency of false positive results.

The European autoimmune disease diagnostic market is basically segmented based on disease type and diagnostics. Based on disease type the market is further segmented as systemic autoimmune disease (rheumatoid arthritis, psoriasis, multiple sclerosis, systemic lupus erythematosus) and localized autoimmune disease (Inflammatory bowel syndrome, Type 1 diabetes, thyroid and others). Based on diagnostics, the market is segmented as Immunofluorescence assays, enzyme linked immnosorbent assay, western blotting, dot blot, line blot, multiplex immunoassay, agglutination, double immune diffusion and counterimmuno electrophoresis.

Based on geographical location, the Europe autoimmune disease diagnostic market can be broadly divided into France, UK, Germany, Spain, Portugal, Scandinavia and Italy.

European Union funded research projects like PRECISESADS and the high prevalence of the disease in Europe are some of the market opportunities for the market players. However, they face the challenge to deal with a shortage of skilled personnel who can operate the technology. The key players are F.Hoffmann-La Roche, Novartis AG, Pfizer Inc., Eli Lilly among many others.

Key Deliverables in the Study

Market analysis for the Europe Autoimmune Disease Diagnostic Market, with region specific assessments and competition analysis on regional scales.

Market definition along with the identification of key drivers and restraints

Identification of factors instrumental in changing the market scenarios, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their market.

Identification and analysis of the macro and micro factors that affect the Europe Autoimmune Disease Diagnostic market on regional scales

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information

A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market

Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped


1.1 Study deliveratives

1.2 Market Definition

1.3 Sizing Units

1.4 Base Currency

1.5 Review and forecasr period years

1.6 General Study Assumptions


2.1 Introduction

2.2 Analysis Methodology

2.3 Econometric forecast models

2.4 Research Assumptions




5.1 Current market scenario

5.2 Technology Overview

5.3 New developments in therapeutics

5.4 Investment analysis

5.5 Porters Five Force Analysis

5.5.1 Bargaining Power of suppliers

5.5.2 Bargaining power of buyers

5.5.3 Degree of competition

5.5.4 Threat of substitution

5.5.5 Threat of new entrants


6.1 Market Drivers

6.1.1 Growing Public awareness of autoimmune disease

6.1.2 Improved Laboratory Automation

6.1.3 Partnerships with Physicians and Clinical Laboratories

6.1.4 Technological innovation

6.2 Market Restraints

6.2.1 Slow turnaround Time for Autoimmune Disease Diagnostic Test Results

6.2.2 High frequency of false positive result

6.3 Market opportunities

6.3.1 EU funded research projects like PRECISESADS

6.3.2 High prevalence of autoimune disease in Europe

6.4 Key Challenges

6.4.1 Shortage of skilled personnel

7. Europe Autoimmune Disease Diagnostic market segmentation

7.1 By disease type

7.1.1 Systemic autoimmune disease Rheumatoid Arthritis Psoriasis Systemic Lupus Erythematosus (SLE) Multiple Sclerosis Others

7.1.2 Localized autoimmune disease Inflammatory Bowel diesease Type 1 Diabetes Thyroid Others

7.2 By Diagnostics

7.2.1 Immunofluorescence assays (IFA)

7.2.2 Enzyme-linked Immunosorbent Assay (ELISA)

7.2.3 Western Blotting

7.2.4 Dot blot

7.2.5 Line blot

7.2.6 Multiplex immunoassay

7.2.7 Aggultination

7.2.8 Double immune diffusion

7.2.9 Counterimmunoelectrophoresis

8. Europe Autoimmune Disease Diagnostic market by Geography - Regional shares and forecast

8.1 Introduction

8.2 France

8.3 UK

8.4 Germany

8.5 Spain and Portugal

8.6 Scandinavia

8.7 Italy

8.8 Rest of Europe

9. Competitive Landscape

9.1 Merger and Acquisition Analysis

9.2 New Product Launches

9.3 Agreements, Collaborations & Partnerships

10. Company Profiles

10.1 F.Hoffmann-La Roche,

10.2 Novartis AG

10.3 Sanofi-aventis

10.4 Astrazeneca

10.5 Lycera

10.6 Pfizer Inc.

10.7 Celgene Corporation

10.8 Bristol-Myers Squibb

10.9 Eli Lilly

11. Analyst Outlook for Investment Opportunities

12. Future Outlook of the Market

Content are not available

Choose License Type